Pan-Amyloid Removal Therapeutics by Attralus: A Novel Approach to Systemic Amyloidosis | Mark Timney, CHIEF EXECUTIVE OFFICER, ATTRALUS 00:10:00
Mark Timney has deep experience in the biopharmaceutical industry. He has repeatedly distinguished himself as a corporate leader who delivers value for patients and shareholders. In addition to his role as Chairman of the Board with Blade, Mark currently serves as Chief Executive Officer at Attralus and a board member at Sarissa Capital Acquisition Corp. (NASDAQ: SRSAU). He is also a strategic advisor to health care companies and investment groups.
